title: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
abstract: OBJECTIVE
  Gonadotropin-releasing hormone (GnRH) agonists are associated with greater risk of coronary heart disease and myocardial infarction in men with prostate cancer, but little is known about potential impact on cardiovascular mortality. We assessed the relationship between GnRH agonists and cardiovascular mortality in a large randomized phase III trial of men treated with or without adjuvant goserelin after radiation therapy (RT) for locally advanced prostate cancer.
  
  
  METHODS
  Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone. Fine and Gray's regression was used to evaluate treatment effect on cardiovascular mortality. Covariates included age, prevalent cardiovascular disease (CVD), hypertension, diabetes mellitus (DM), body mass index, race, Gleason score, stage, acid phosphatase level, prostatectomy history, and nodal involvement.
  
  
  RESULTS
  After a median follow-up of 8.1 years, there were 117 cardiovascular-related deaths but no treatment-related increase in cardiovascular mortality. At 9 years, cardiovascular mortality for men receiving adjuvant goserelin was 8.4% v 11.4% for men treated without adjuvant goserelin (Gray's P = .17). In multiple regression analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR] = 0.73; 95% CI, 0.47 to 1.15; P = .16; when censoring at time of salvage goserelin therapy, HR = 0.99; 95% CI, 0.58 to 1.69; P = .97). Traditional cardiac risk factors, including prevalent CVD and DM, were significantly associated with greater cardiovascular mortality.
  
  
  CONCLUSIONS
  GnRH agonists do not seem to increase cardiovascular mortality in men with locally advanced prostate cancer. Further studies are warranted to evaluate adverse effects of GnRH agonists in men with lower cancer-specific mortality.
authors.affiliation: Department of Radiation Oncology and Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Jason A
authors.initials: JA
authors.lastname: Efstathiou
authors.forename: Kyounghwa
authors.initials: K
authors.lastname: Bae
authors.forename: William U
authors.initials: WU
authors.lastname: Shipley
authors.forename: Gerald E
authors.initials: GE
authors.lastname: Hanks
authors.forename: Miljenko V
authors.initials: MV
authors.lastname: Pilepich
authors.forename: Howard M
authors.initials: HM
authors.lastname: Sandler
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000401:mortality*; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012044:Regression Analysis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin